Transpire Bio Announces Opening of New Satellite R&D Facility in Shanghai, China

 Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, has opened its new satellite R&D facility in Shanghai, China.

"As Transpire Bio continues to execute its strategic plan of building a legacy as an innovator in inhalation-based therapies, we are pleased to announce the grand opening of our Shanghai R&D center," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio. "This team of inhalation scientists and device engineers will be focused on our next generation inhalation device platforms as well as generic substitutable and hybrid inhalation product candidates intended for markets in the EU, UK, and APAC regions, further expanding our ability to innovate and bring new therapeutic options to patients around the world."